In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Johnson & Johnson is one of them.
Johnson & Johnson, a global healthcare leader, continues to strengthen its pharmaceuticals and immunology portfolio while delivering strong stock performance in 2025.
This month, the company received FDA approval for a subcutaneous induction regimen of Tremfya (guselkumab) to treat adults with ulcerative colitis. As the first and only IL-23 inhibitor with a fully subcutaneous regimen, Tremfya achieved significant clinical remission and endoscopic improvement in Phase 3 trials. JNJ is also launching a head-to-head trial comparing Tremfya to AbbVie’s Skyrizi in Crohn’s disease, underscoring its commitment to expanding in immunology.
In Europe, Johnson & Johnson reported progress for nipocalimab, an investigational FcRn blocker for antibody-positive generalized myasthenia gravis in both adults and adolescents. Pending European Commission approval, it could become the first treatment of its kind, supported by compelling late-stage trial data.
The business also expanded its oncology portfolio with FDA approval of a new drug delivery system for bladder cancer, offering patients a potential alternative to surgery and reinforcing its position in cancer innovation.
On the financial front, Johnson & Johnson’s shares are up 20% year-to-date, boosted by pharmaceutical growth and easing legal risks compared to previous years. Still, the company continues to navigate ongoing talc-related litigation, with settlements and court proceedings drawing attention.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW
